Liver disease is associated with profound and characteristic changes in lipoprotein composition and metabolism. The most pronounced alterations are the Formation of lipoprotein-X in intra-and extrahepatic cholestasis, the decrease of apolipoproteins A-I and A-II and the increase of apolipoprotein E. These alterations impair the activities of both lipoprotein lipase and lecithin : cholesterol acyltransferase. They are also responsible for an abnormal receptor mediated uptake of the lipoproteins from plasma. The abnormal lipid and apolipoprotein composition of the lipoproteins in liver disease % appears to affect various important functions of cell membranes. The understanding of how these changes occur and their significance in the pathogenesis of other metabolic disturbances secondary to the abnormal lipid metabolism are important challenges for future research.
Introduction
Lipids serve both äs a major energy source and äs structural components of cell membranes. Not surprisingly, their homeostasis is carefully maintained by a number of iiiterrelated metabolic pathways, not only of the lipids but also of the carbohydrates and proteins. The insolubility of lipids in aqueous fluids adds complexity to the transport processes in plasma by creating a need for a carrier System. Tttis carrier System of protein-lipid aggregates or lipoproteins has been the subject of intense investigation for many years. The basic achievements of the last three decades, which have led tö ä better understanding of the biochemistry and pathobiochemistry of lipids in health and disease, arose from the characterization of the lipoprotein System in terms of the structural properties and metabolism of the plasma lipopro* teins. The association between plasma lipid concentrations and cardiovascular risk was withoüt doubt the major Stimulus in clinical research on plasma lipidis. However, lipid disturbances ocourring in liver disease and in particülar the hypercholesterolaemia accompanying biliary obstruction, a phenomeiion recorded first by Flint (1) over a Century ago, are among the oldest lipid disorders known to clinical medicine.
The data discussed in this review are intended to demonstrate that liver dysfunction produces complex derangements of the lipoprotein System. The basic defects seem to be a disturbed hepatic biosynthesis of lipoproteins, a disturbed hepatic removal of lipoproteins from the circulation and a disturbed plasma lipolytic activity.
Nature of Lipoproteins in Plasma
The liver plays a central role in the regulation of lipoprotein synthesis and degradation äs well äs in the storage of lipids in various tissues. Therefore, liver dysfunction can be associated with hyper-, hypo-, dys-or paralipoproteinaemia. Any approach to an appreciation of the pathobiochemical significance of the various normal and abnormal plasma lipoprotein patterns requires a consideratioü of the multifaetorial control mechanisms regulating the lipoprotein system. Lipoprotein metabolism covers a broad field and cannot be fully suminarized in a review such äs this (for further Information see 1. c. (2, 3) ).
Important terms and Steps in lipoprotein metabolism can be summarized äs follows:
-intestinal absorption of lipids; -rates of synthesis of lipids and apolipoproteins; -assembly and secretion of lipoproteins; -structure of lipoproteins and apolipoproteins; -interconversion and intravascular catabolism of lipoproteins mediated by plasraa-lipases and lecithin: cholesterol acyltransferase; -recognition, uptake and catabolism of lipoproteins by hepatic and extrahepatic cells; -transformation and elimination of lipids and steroids by the liver.
The plasma lipoproteins are water-soluble macromolecular complexes heterogenous in size and composition, with relative molecular weights of up to several million and a particle sizes in the ränge 7 -1000 nm (see fig. 1 ). fractions exhibit varying degfees of heterogeneity and differences in size and protein lipid composition. The lipoproteins can also be separated by electrophoretic methods in various supporting media (6, 7) . Accordî ng to their electrophoretic migration they are classified äs pre-ß-(VLDL), ß-(LDL) and a-Jipoproteins (HDL pase, and the phospholipases), three are synthesized in the liver, i. e. lecithin : cholesterol-acyl-transferase, hepatic triglyceride lipase and phospholipase.. Other important cellular enzymes involved in lipid metabolism, such äs acyl-CoA: cholesteryl-acyl-transferase (ACAT), hydroxymethylglutaryl-CoA-reductase, hydroxymethylglutaryl-CoA-synthase, cholesterol-ester-hydrolase, enzymes of fatty acid and phosphölipid synthesis and cholesterol 7-a hydrolase are also hepatic enzymes.
The Metabolism of Lipoproteins in Plasma
Although it has been assumed for many years that the terminal catabolism of mammalian plasma lipoproteins occurs predominantly in the liver, most detailed investigations of receptor mediated processing of macromolecules in this organ have until recently not been concerned with plasma lipoproteins, but rather with other plasma proteins, polypeptides and hormones. The first detailed studies on receptor mediated endocytosis of lipoproteins in the liver were facilitated by the discovery that administration of pharmacological amounts of öestradiol to rats in* duces a several fold increase in the number of LDLreceptors on the surface of hepatocytes and increases the uptake and catabolism of LDL by the liver (11) . From combined biochemical and morphological approaches it was possible to show that the various' steps to lipoprotein binding to receptors, intemalisatiön, movement to the lysosomal regiön and lysosomal processing resemble clösely those described for LDL in fibroblasts (12,13) and other macromolecules in hepatocytes (see fig. 3 ). Cholesterol taken up by hepatocytes suppresses hydroxymethylglutaryl-CoAr eductase, activates acyl CoA: cholesteryl acyltransferase, inhibits expression of LDL receptors but leaves apolipoproteiri E receptor activity unchanged (14, 15) . LDL binds to the receptor via a single site on apolipoprotein B. Also VLDL remnants bind to this receptor but with much higher affinity than that of LDL, presumably because these particles possess apolipoprotein E and bind polyvalently to the LDLreceptor. These differences in affinity have major consequences for lipoprotein catabolism, since VLDL remnants are removed from the blood within minutes, whereas LDL circulates for many hours (16, 17) . Since it has been estimated that the liver clears more than 80% of the structural lipids, phospholipids and cholesterol from the circulation (18) it is important to realize that more than one receptor seems to participate in hepatic lipoprotein catabolism and that processes other than receptor mediated endocytosis may also participate in hepatic lipoprotein metabolism. Studies in a mutant rabbit that lacks LDLreceptors (Watanabe hereditary hyperlipidaemic, WHHL, rabbit) have provided evidence that LDLreceptors are not necessary for uptake of chylomicron remnants by the liver (19) . Uptake of chylomicrons by hepatic parenchymal cells in these animals seems to occur via a distinct chylomicron remnant receptor, the apolipoprotein E receptor, which so far has only been described for hepatocytes. A third lipoprotein receptor, the Scavenger receptor (Scavenger-system), present mainly in reticulo-endothelial cells and also in Kupffer-cells, efficiently removes certain chemically modified and abnormal lipoproteins from the blood (10, 21) . The importance of this pathway for lipoprotein catabolism is uncertain because the extent to which lipoproteins are modified in vivo so äs to permit them to be recognized by the Scavenger receptor is still unknown. On the other hand, LDL and possibly also VLDL remnants are also taken up by hepatocytes of WHHL-rabbits, which may indicate the existence of other, äs yet undefined processes capable of Clearing these lipoproteins from the circulation (22) . Also binding sites for high density lipoproteins (HOL) have been postulated for hepatocytes and demonstrated in membrane preparations of rat liver (23) . This process however, may not involve endocytosis, because the rates of uptake of lipids and the apolipoproteins by this System are different.
The role of the liver in the synthesis of apolipoproter ins and lipids, their assembly in the Gö/£/-apparatüs and the secretion of lipoproteins was established in the late 50's and then became the focus of a great deal of research (for definition see 1. c. (24)). It was appreciated that the rate of synthesis .and secretion of these particles by the liver is an important determin ant of their circulating levej. Secretion and degradation are equally important in detennining lipoprotein levels because in the steady state the rate of synthesis must equal the rate of degradatipn, and a change in either will cause a change in the circulating level.
The role of the liver in the regulation of the plasma lipoprotein System can briefly by outlined äs follows (see fig. 4 ):
The liver secretes two types of nascent lipoproteins: nascent VLDL which is rieh in triglycerides and apolipoprotein B but contains very little apolipoprotein C and apolipoprotein E, and nascent HDL which is rieh in phospholipids, unesterified cholesterol, apolipoprotein E and apolipoprotein A-II and contains some apolipoprotein C. These particles possess laminar structures and are found within the density class d l .063 -l .21 kg/l on ultracentrifugation. After nascent HDL particles enter the plasma they are acted upon by lecithin : cholesterol acyltransferase, an enzyme also synthesized and secreted by the liver. Cholesterol is esterified, thus rendering it hydrophobic, and it is thereby transferred into the core of the particles. This brings about a change in the shape of the particles into a globular form. At the same time there is an exchange of apolipoprotein E and apolipoprotein C with apolipoprotein A-I, the cofactor for lecithin: cholesterol acyltransferase which is primarily derived from the intestine. By this mechanism mature HDL is generated, and it is believed that these particles leave the circulation by an uptake mechanism in the liver, which* however, has not yet been fully elucidated. During the esterification of HDL-cholesterol, apolipoprotein C and apparently apolipoprotein E is transferred to the pathway leading from nascent to mature VLDL, intermediate-density lipoproteins (IDL) and finally to LDL. This metabolic cascade is regulated by lipoprotein lipase and by hepatic-triglyceride-hydrolase, the two major enzymes of postheparin plasma lipolytic activity. During triglyceride hydrolysis some apolipoprotein C and apolipoprotein E is transferred back to the HDL density class. It has been postulated that these apolipoproteins form, together with apolipoprotein A-I, apolipoprotein D, lipid transfer proteins and lecithin: cholesterol acyltransferase, the so-called Reversed CholesteroJ Transport Complex (RCTC), by which cholesterol is transferred from the peripheral cells to the liver for excretion.
The Abnormal Lipoprotein Profile in Liver Disease
From the complex metabolic pathways of the plasma lipoproteins in which the liver is predominately involved it is clear that abnormal liver function may cause profoünd disturbances in the lipoprotein system. The abnormal patterns, however, are generally not indicative of a particular liver disease. Therefore in the following descripüon emphasis will be placed on the pathöbiochemical aspects, rather than attempting to directly link a particular lipoprotein or lipid pattern to a specific liver dysfunction. The following abnormalities in plasma lipids, lipoproteins and apolipoproteins may occur äs a result of liver dysfunction: -hypercholesterolaemia; -increased ratio of free to esterified cholesterol; -hyperphospholipidaemia; -normal or eleväted levels of plasma triglycerides; -increased or decreased concentration of LDL; -normal or eleväted levels of VLDL, often with abnormal (ß-) mobility on electrophoresis; -normal or decreased levels of HDL with a marked heterogeneity and abnormal composition of HDL particles; -decreased concentrations of apolipoproteins A and B-100; -eleväted concentration of apolipoprotein E; -increased concentrations of IDL and apolipoprotein B-48; -decreased plasma post-heparin lipolytic activity; -eleväted or reduced activity of lecithin: cholesterol acyltransferase; -appearance of the abnormal lipoprotein-X (LP-X) in cholestasis.
Electrophoresis of lipoproteins in liver disease reveals a typicäl pattern of only one, often broadened, band in the ß-position, which masks a heterogeneity which can only be elucidated by the employment of various analyticäl techniques (25) . Drastic changes in the concentration of apolipoproteins. often occur concomitantly with this lipoprotein pattern, but they are not disease-specific (26, 27) . The normalization of these chatnges, höwever, may be helpful in following the course of the disease.
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Cholestasis and Hypercholesterolaemia
Several years ago we were able to show that the lipoprotein pattern of cholestasis is mainly characterized by the appearance of an abnormal lipoprotein particle in the LDL density olass. This particle has been subsequently isolated and characterized with respect to its physicochemical properties. It has been designated lipoprotein-X (28, 29). Lipoprotein-X has the characteristics of a vesicle, in which a phospholipid-cholesterol-apolipoprotein membrane structure separates an internal from an external water compartment. Its mean diameter is approximately 50 -70 nm.
The disc-formation seen on electron micrographs is not unique for this particle (30). Similar laminar structures have been described for artificial lipidprotein complexes; they have also been demonstrated in the plasma of cholesterol-fed animals, äs well äs in the plasma of patients with lecithin: cholesterol acyltransferase deficiency (31, 32).
The protein-lipid compositioii of lipoprotein-X is unique, and is characterized by a high content of phospholipids and a low content of cholesterol esters (28). Bile salts are bound to lipoprotein-X and, depending on their concentration, may exert a strong infruence äs a detergent on the physicochemical properties of the particle (33). Albumin accounts for up to 60% of the protein component of lipoprotein-X and is primarily located inside the vesicle (29). In cöntrast, the specific apolipoproteins of lipoprotein-X (apolipoprotein C and apolipoprotein D) are located on the surface. Apolipoprotein B, the major apolipoprotein of LDL and also apolipoprotein E are not present in lipoprotein-X. In addition, aggregates of various liver and bile enzymes, such äs alkaline phosphatase or -glutamyltransferase with lipoprotein-X have been described, but have been erroneously interpreted äs isoenzymes (34, 35, 36). The detection of lipoprotein-X in the serum pf a patient is the most sensitive and specific clinical chemical parameter for the diagnostic confirmation or exclusion of cholestasis, äs shown by a large nümber of clinical studies (for further Information see L c. (37)).
The appearance of lipoprotein-X iii plasma has been noted after t bile duct Jigation in experimental laboratory animals and after insertion of the common bile duct into the venous System (38).
In addition, incubation of bile lipoproteins with serum leads to a complete conversion of the bile lipids into lipoprotein-X (33). The data from both the in vitro and in vivo experiments indicate that the bile lipids are converted into lipoprotein-X when they enter the plasma compartment, äs in cholestasis. The finding that lipoprotein-X or its precursors are formed in experiments in which only biliary lipids and albumin are incubated together is of particular theoretical and pathobiochemical significance. Such precursors exhibit a high affmity for apolipoprotein C and apolipoprotein D, which in the vascular space may bring about disturbances in the balance or exchange of these apolipoproteins between VLDL and HDL (see fig. 4 ), a mechanism which is important for plasma lipoprotein metabolism. The hypertriglyceridaemia of cholestasis may be caused by such a mechanism, a view which is supported by the observation that these apolipoproteins are either absent or drastically reduced in VLDL particles obtained from patients with cholestasis (25, 27) .
Results from Wallt et al. in our laboratory (39) concerning the catabolism of lipoprotein-X, revealed that lipoprotein-X is like other macromolecules taken up and catabolized by the reticuloendothelial System, primarily by the spieen and not äs most normal plasma lipoproteins by the liver. Moreover receptorbinding studies iijdicate that isolated hepatocytes or fibroblasts exhibit a low degree of binding and uptake of lipoprotein-X, whereas in lymphocytes high rates are observed and these cell types show a marked reduction in the activity of the hydroxymethylglutaryl-CoA-reductase when in contact with lipoprotein-X. Also, the reductase activity is greatly depressed in lymphocytes from cholestatic patients.
Normally chylomicron remnants are rapidly removed from the circulation by the liver and are most effective in suppressing hepatic cholesterolgenesis. Lipoprotein-X causes a marked Inhibition of remnant uptake by isolated perfused livers and isolated hepatocytes, even though it is devoid of apolipoprotein B and apolipoprotein E and is not taken up by hepatocytes itself (14, 39) .
A parallel clinical finding is hypertriglyceridaemia with persisting apolipoprotein B-48, which is often noted in cholestatic patients and is indicative of the accumulation of remnant-like particles (40). In cön-trast to the direct effects of lipoprotein-X on chylomicron remnant uptake, no such effects of lipoprotein-X on the degradation of LDL by isolated perfused livers or monolayer cultures of skin fibroblasts are noted (l 5, 39). In order to understand the relevance of these in vitro results for the Situation in vivo, we perfused livers from cholestatic rats which had lipoprotein-X in their serum. Such livers degraded twice äs much [ 125 I]LDL äs normal livers. A similar Situation is observed in patients with cholestasis. The apolipoprotein B concentration in the serum of cholestatic patients is re-duced to half ofthat found in normal subjects, reflecting a reduced LDL concentration. Also, in the isolated perfused liver lipoprotein-X stimulates the key enzyme of cholesterol synthesis, hydroxymethylglutaryl-CoA-reductase, by a factor of 2.5 (14, 39) . Taken together, these observations are of particular interest with respect to both hepatic lipoprotein receptor activity and cholesterolgenesis in hepatocytes. Although lipoprotein-X is devoid of apolipoprotein B and apolipoprotein E, it appears to affect apolipoprotein E receptors directly, but hepatic LDL receptor activity indirectly. The mechanism by which lipoprotein-X affects the function of the hepatic apolipoprotein E receptor is äs yet unknown but presents an important challenge for future research in this field.
intake of alcohol (45, 46) seems to be caused by an accelerated turn-over of very low density lipoproteins. Nikkilä et al. (47) found both the fractional catabolic rate of VLDL and the turn-over rate of VLDL to be high in alcoholic men, and they normalized following two weeks of abstinence. However, the removal of triglycerides from plasma is not increased by acute alcohol intake but rather impaired. Continued use causes a gradual return to normal concentrations of VLDL. This change parallele an increase in lipoprotein lipase activity (47). The reason for the decrease of plasma LDL concentration follöwiiig heavy alcohol consumption rernains to be elucidated (46). Both elevated HDL and reduced LDL return rapidly to normal after alcohol withdrawal.
Hypertriglyceridaemia
Clinical studies first indicated that hypertriglyceridaemia is also frequently found in severe cholestasis and in primary biliary cirrhosis (41, 42).
The main increase in triglycerides is found in the LDL-II density class. Triglyceride-rich, cholesterolpoor apolipoprotein B, apolipoprotein C and apolipoprotein E-containing intermediate density lipoproteins account for the accumulation of tryglycerides in this density fraction (43). These unusual particles are heterogeneous in size, ranging from 30 nm to 80 nm, and are thus much larger than normal LDL (20 -25 nm) . Dietary studies have indicated that these particles are remnants derived from a disturbed catabolism of chylomicrons (25) . Their accumulation may be caused by reduced plasma lipolytic activity and/or by a disturbed hepatic uptake due to an Inhibition of the apolipoprotein E receptor. Jahn et al. recently demonstrated a decreased activity of hepatic lipase in all his patients with primary biliary cirrhosis due to the presence of a heat labile enzyme Inhibitor (44). In contrast, altered cholesterol esterification was only observed in subjects with advanced disease.
Influence of Alcohol Intake on the Lipoprotein System
Hypertriglyceridaemia äs a consequence of liver damage by alcohol is also well known, but not fully understood. The metabolic Situation is complicated, äs acute and chronic intake of alcohol may bring about opposing disturbances in lipid metabolism. Moreover the quaritity of alcohol consumed is important.The well-documented increase in plasma HDL concentration following a constant, but non-toxic e
HDL and a-Lipoproteins
The HDL fraction in liver disease contains hardly any cholesterol esters or triglycerides, while the conĉ entration of free cholesterol and phospholipids is increased. The -lipoproteins cannöt be visualized on lipoprotein electropherograms (25, 27) . Ultracentrifugal and Chromatographie analysis, höwever, reveal the presence of lipoproteins in this density class but with an unusual degree of heterogeneity. Ünder the electron microscope most particles show rouleaüx förmatiön similar to lipoprotein-X or nascent HDL particles. The rates of apolipoprotein A-I catabolism and elimination are increased by 2-4 föld in acute alcohol hepatitis, äs compared with healthy contföl subjects (48). From this observation i t may be concluded that the diminished plasma concentration of apolipoprotein A found in liver patients is primarily due to its accelerated catabolism, rather than to ä disturbed synthesis, äs described for Tangier disease, a primary deficiency of HDL (49). The apolipoprotein A-I and apolipoprotein A-II in the plasma of patients with liver disease often show a complete dissociation and they lose much of their lipid binding capacity (25) . It is possible that the dissociation of the two apolipoprotein A sübünits is a inajor reason for their accelerated catabolism and this may well result from a disturbed generation of mature HDL from nascent HDL in the plasma of such patients, emphasizing the general importanee of the structural properties of a lipoprotein with respect to its metabolism. The HDL fraction in most patients with liver disease not only shows decreased .concentrations of their major apolipoprotein constituents, apolipoprotein A-I and apolipoprotein A-II, but also a marked increase in apolipoprotein E (50), a phenomenön which has also been described for familial leci-thin: cholesterol acyltransferase deficiency when such patients are subject to a dietary cholesterol load. Recently Owen et al. (51) reported that a subfraction of HDL, containing primarily applipoprotein E, strongly reduced LDL binding, internalization and degradation in cultured human skin fibroblasts. In contrast to normal HDL, these HDL particles were also taken up and degraded by the fibroblasts apparently through the LDL-receptor pathway. The particles also stimulated cellular cholesterol esterification, increased cellular cholesterol ester content and suppressed cholesterol synthesis and receptor activity (51). It was concluded from these results that this particulate HDL may deliver cholesterol to the cells via LDL-receptor mediated uptake. It should be interesting to elucidate whether in cirrhotic patients. It is reasonable to anticipate that apolipoprotein E accumulates in the HDL fraction äs a consequence of plasma lecithin : cholesterol-acyl-transferase deficiency.
In collaboration with Dr. Clemens from the University of Tübingen, Drs. Armstrong and Wallt from our laboratory were able to demonstrate lipoproteins with abnormal binding characteristics to lipoprotein receptors in all three major density classes of a patient suffering from familial lecithin: cholesterol acyltransferase deficiency. An abnormal HDL rieh in apolipoprotein E with high affinity to heparin-sepharose revealed a high binding affinity to the LDL receptor in cultured fibroblasts, while a small sized LDL from this patient showed a lower than normal affinity to the LDL-receptor (52). In isolated perfused rat livers the HDL fraction rieh in apolipoprotein E was degraded more rapidly than any other lipoprotein isolated from the plasma of the patient.
The data discussed in this review indicate that liver dysfunction produces complex derangements of the lipoprotein System, The basic defects seeni to be a disturbed hepatic biosynthesis of lipoproteins, a disturbed hepatic removal of lipoproteins from the circu·* lation and a disturbed plasma lipplytic activity. This Suggestion is strongly supported by the finding of struetural similärities betweeii naseent VLDL and nascent HDL with the plasma VLDL and HDL accumulating in liver disease patients.
Plasma .Lipoproteins and Plasma Membranes
We have described and discussed some of the most ! common abnormalities of lipoproteins, apolipoproteins and lipoly tic enzymes, disturbances of metabolic regulation and altered lipoprotein-receptor activities found in liver disease. Since most plasma lipoproteins, normal or abnormal, interact with cell surface membranes and since cell membrane fluidity is known to alter the capacity of cells for many important biological mechanisms, it is reasonable to anticipate that alterations of the lipoprotein System in liver disease may have important consequences for a number of cellular functions including carrier mediated transport, the properties of certain membrane-bound enzymes, the binding to specific receptors, endocytosis, depolarization dependent exocytosis, immunological cytotoxicity, prostaglandin production, cell growth and possibly for many other äs yet unknown cell functions (53, 54). The effects of lipid modification and cellular function were, however, very complex. They often vary from one type of cell to another and they do not exert a uniform effect on all processes in a single cell line. Therefore, it is not yet possible to make any generalizations or to predict how a given cell System may respond to a particular type of lipid modification. Many of the functional responses probably are caused dlrectly by the changes in membrane lipid structure which affect either bulk lipid fluidity or specific lipid domains. The confonnation or quaternary structures of certain transport proteins, receptors or enzymes probably are sensitive to changes in the structure of their lipid microenvironement. This may lead to changes in their biological activity. The dynamic state of lipids in membrane bilayers was first described by Singer & Nicolson in 1972 (55) äs one of the fundamental factors of the fluid mosaic model of membrane structure. The basic question to be raised now is whether and to what extent the interaction or exchange of membrane lipids with abnormal lipoproteins in liver disease can modulate cell membrane composition and consequently the activity of membrane proteins. The immediate change in the shape of red blood cells by incubation with lipoproteins from liver disease patients (56), and the abnormal erythrocytes (57, 58) and abnormal platelet aggrega-. tion in human liver disease (59) indicate that it may be possible to investigate this problem. Also the Inhibition of hepatic apolipoprotein E receptor (14, 15, 39) by lipoprotein-X which is devoid of the protein ligand to the receptor (29) may be a consequence of an altered cell membrane fluidity deriving from the interaction with lipoprotein-X. The hyperglycaemia of liver disease may be another example of such a general pathobiochemical mechanism.
It now seems important and interesting to further correlate abnormal functions of organs and cells with the abnormal composition of plasma lipoproteins in liver disease.
